biological products

Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets
Huiqiong Zeng, Yu Zhuang, Xiaodong Yan, Xiaoyan He, Qianwen Qiu, Wei Liu, Ye Zhang

Lupus Science & Medicine Apr 2024, 11 (1) e001126; DOI: 10.1136/lupus-2023-001126
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count
Guillaume Germain, Karen Worley, Sean D MacKnight, Bernard Rubin, Christopher F Bell, François Laliberté, Ana Urosevic, Mei Sheng Duh, Andrew Concoff

Lupus Science & Medicine Apr 2024, 11 (1) e001111; DOI: 10.1136/lupus-2023-001111
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie

Lupus Science & Medicine Mar 2024, 11 (1) e001112; DOI: 10.1136/lupus-2023-001112
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE
Aaron Bao, Michelle A Petri, Andrea Fava, Jun Kang

Lupus Science & Medicine Dec 2023, 10 (2) e001007; DOI: 10.1136/lupus-2023-001007
Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus
Ting-Wei Lin, Yu-Tsan Lin, Ya-Chiao Hu, Hsin-Hui Yu, Bor-Luen Chiang

Lupus Science & Medicine Jan 2024, 11 (1) e000987; DOI: 10.1136/lupus-2023-000987
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger A Levy, Deven Chauhan, Nick Ballew

Lupus Science & Medicine May 2023, 10 (1) e000907; DOI: 10.1136/lupus-2023-000907
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial
Fangfang Sun, Wenyan Huang, Jie Chen, Liling Zhao, Danting Zhang, Xiaodong Wang, Weiguo Wan, Sheng-Ming Dai, Sheng Chen, Ting Li, Shuang Ye

Lupus Science & Medicine Feb 2022, 9 (1) e000638; DOI: 10.1136/lupus-2021-000638
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
Herbert Struemper, Milena Kurtinecz, Lisa Edwards, William W Freimuth, David A Roth, William Stohl

Lupus Science & Medicine Feb 2022, 9 (1) e000499; DOI: 10.1136/lupus-2021-000499
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
Kenei Sada, Noriaki Kurita, Hisashi Noma, Taizo Matsuki, Holly Quasny, Roger A Levy, Angela R Jones-Leone, Kerry Gairy, Nobuyuki Yajima

Lupus Science & Medicine Sep 2022, 9 (1) e000746; DOI: 10.1136/lupus-2022-000746
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
Jacob N Hunnicutt, Jolyon Fairburn-Beech, Mary Elizabeth Georgiou, Anna Richards, Yun Irene Gregan, Holly Quasny, Deven Chauhan

Lupus Science & Medicine Nov 2022, 9 (1) e000710; DOI: 10.1136/lupus-2022-000710

Main menu

biological products

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

biological products

Pages